The efficacy, functions and side effects of tucatinib

Tucatinib is an innovative, targeted drug designed to treat HER2-positive breast cancer, a malignant disease that has spread to other parts of the patient’s body and for which surgery is no longer a viable option for patients who have already experienced at least one treatment option. In addition to breast cancer, tucatinib, in combination with trastuzumab, has shown potential in treating certain types of colorectal cancer that have also metastasized and become resistant to previous chemotherapy drugs, making the disease difficult to control with surgery.

In terms of efficacy, tucatinib effectively slows down the growth and spread of cancer cells by precisely inhibiting the activity of HER2, bringing significant clinical benefits to patients. In combination with trastuzumab and capecitabine, tucatinib can enhance the overall treatment effect, extend patients' progression-free survival, and improve their quality of life. For refractory cases such as brain metastases, tucatinib has also shown excellent efficacy.

However, like other drugs, tucatinib may be associated with some side effects. Common symptoms include diarrhea, nausea, vomiting, fatigue and other digestive and nervous system-related symptoms. In addition, redness, swelling, and pain on the palms and soles of the feet are also reactions that some patients may experience. Although these side effects are manageable in most patients, they require close monitoring and prompt management.

In general, tucatinib, as an efficient and relatively safe targeted therapy, brings new hope to patients with HER2-positive breast cancer and certain types of colorectal cancer. Its unique efficacy and manageable side effects make it occupy an important position in modern cancer treatment.